Benefits attending:

• Assess new industry directions through the latest data from ophthalmic clinical trials
• Review advanced techniques in treating age-related diseases of ophthalmology
• Explore evolving therapeutic potential in undruggable diseases through innovative gene therapies
• Examine novel methodologies in delivery technologies being used to further the ophthalmic therapeutic field
• Engage in the regulatory landscape of ophthalmic drugs and key considerations for R&D

who should attend:

- Heads and VPs of Retinal Health, Ocular Therapy, Medical Safety, and Ophthalmology.

- Professors, Senior Lecturers, and Specialists in Ocular biology and immunology, and clinical pharmaceuticals.

- CEOs, CMOs and Researchers from pharmaceutical companies involved in ocular drug development, in addition to biotechnologies involved in ocular drug delivery research.
 

Aerie Pharmaceuticals; Alcon Management SA; Boehringer Ingelheim Biopharmaceuticals Gmbh; Carl Zeiss AG; Centro de Oftamologia Barraquer; Experimentica Ltd; Eyenuk; Global Ophthamology R&D, Santen Inc, USA; Graybug Vision Inc; iVeena; Iveric Bio; Kingston University; Kingston University London; Medicines & Healthcare products Regulatory Agency (MHRA); Medivis; MedPharm Ltd; MHRA; Nanoptima Ltd; Newcastle University; Novartis Pharmaceutical inc; Ophthalmic Drugs 2019; Ophthalmology Times Europe; Optceutics Ltd; ProMed Pharma, LLC; ProQR Therapeutics; RAFARM S.A. Pharmaceuticals; Roche; Roche Products Limited; Santen UK; Spark Therapeutics; Thea Open Innovation; Topivert; twoXAR; UCL Institute of Ophthalmology; UCL School of Pharmacy and UCL Institute of Ophthalmology; University of Oxford; University of Reading; University of Strathclyde;

Unfortunately, we do not yet have the detailed scientific program. We are continuing our research. 

Registration required. Please contact the organizer for further information.